JP2007535522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535522A5 JP2007535522A5 JP2007510045A JP2007510045A JP2007535522A5 JP 2007535522 A5 JP2007535522 A5 JP 2007535522A5 JP 2007510045 A JP2007510045 A JP 2007510045A JP 2007510045 A JP2007510045 A JP 2007510045A JP 2007535522 A5 JP2007535522 A5 JP 2007535522A5
- Authority
- JP
- Japan
- Prior art keywords
- dry powder
- powder formulation
- formulation
- glycopyrrolate
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 40
- 239000000843 powder Substances 0.000 claims 31
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 9
- 229940015042 glycopyrrolate Drugs 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 238000004806 packaging method and process Methods 0.000 claims 5
- 230000003750 conditioning effect Effects 0.000 claims 4
- 239000010419 fine particle Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 239000011888 foil Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0409703.6 | 2004-04-30 | ||
| GBGB0409703.6A GB0409703D0 (en) | 2004-04-30 | 2004-04-30 | Pharmaceutical compositions |
| PCT/EP2005/051980 WO2005105043A2 (en) | 2004-04-30 | 2005-04-29 | Pharmaceutical compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011244443A Division JP5124718B2 (ja) | 2004-04-30 | 2011-11-08 | 医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007535522A JP2007535522A (ja) | 2007-12-06 |
| JP2007535522A5 true JP2007535522A5 (enExample) | 2010-03-18 |
| JP5000483B2 JP5000483B2 (ja) | 2012-08-15 |
Family
ID=32408337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007510045A Expired - Lifetime JP5000483B2 (ja) | 2004-04-30 | 2005-04-29 | 医薬組成物 |
| JP2011244443A Expired - Lifetime JP5124718B2 (ja) | 2004-04-30 | 2011-11-08 | 医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011244443A Expired - Lifetime JP5124718B2 (ja) | 2004-04-30 | 2011-11-08 | 医薬組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20080063719A1 (enExample) |
| EP (3) | EP2422766B1 (enExample) |
| JP (2) | JP5000483B2 (enExample) |
| KR (1) | KR101287919B1 (enExample) |
| CN (3) | CN1964700A (enExample) |
| AU (2) | AU2005237266B2 (enExample) |
| BR (1) | BRPI0510500B8 (enExample) |
| CA (1) | CA2563760C (enExample) |
| CY (6) | CY1113069T1 (enExample) |
| DK (2) | DK1755555T3 (enExample) |
| ES (2) | ES2388289T3 (enExample) |
| GB (1) | GB0409703D0 (enExample) |
| HU (4) | HUE025463T2 (enExample) |
| IL (2) | IL178651A (enExample) |
| LT (1) | LTC2422766I2 (enExample) |
| LU (2) | LU92176I2 (enExample) |
| MX (2) | MXPA06012493A (enExample) |
| NO (1) | NO20065502L (enExample) |
| NZ (1) | NZ550479A (enExample) |
| PL (2) | PL1755555T3 (enExample) |
| PT (2) | PT2422766E (enExample) |
| RU (1) | RU2396943C2 (enExample) |
| SG (3) | SG10201605001SA (enExample) |
| SI (2) | SI1755555T1 (enExample) |
| WO (1) | WO2005105043A2 (enExample) |
| ZA (1) | ZA200609350B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| GB0525254D0 (en) * | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0622818D0 (en) * | 2006-11-15 | 2006-12-27 | Jagotec Ag | Improvements in or relating to organic compounds |
| EP2234595B1 (en) * | 2007-12-13 | 2012-11-28 | Novartis AG | Process for reducing the tendency of a glycopyyronium salt to aggegate during storage. |
| US20100266696A1 (en) * | 2007-12-13 | 2010-10-21 | Gerhard Muhrer | Organic Compounds |
| NZ587561A (en) * | 2008-02-26 | 2012-10-26 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist) |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| JP5809985B2 (ja) | 2009-02-26 | 2015-11-11 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | ４−｛（１ｒ）−２−［（６−｛２−［（２，６−ジクロロベンジル）オキシ］エトキシ｝ヘキシル）アミノ］−１−ヒドロキシエチル｝−２−（ヒドロキシメチル）フェノールを含む医薬製剤 |
| CA2759041A1 (en) * | 2009-04-24 | 2010-10-28 | Schering Corporation | Agglomerate formulations useful in dry powder inhalers |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| RU2012138909A (ru) * | 2010-03-31 | 2014-05-10 | Гленмарк Фармасьютикалс Лимитед | Фармацевтическая порошковая композиция для ингаляций |
| RU2585101C2 (ru) * | 2010-04-01 | 2016-05-27 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ приготовления частиц носителя для сухих порошков для ингаляции |
| HUE038555T2 (hu) | 2010-04-21 | 2018-10-29 | Chiesi Farm Spa | Eljárás csökkentett elektrosztatikus töltéssel rendelkezõ részecskék elõállítására |
| AU2011298315B2 (en) | 2010-08-31 | 2014-08-28 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| EP3461474B1 (en) | 2010-08-31 | 2020-11-11 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
| AU2013100007B4 (en) * | 2013-01-04 | 2013-05-23 | Novartis Ag | System for treating chronic obstructive pulmonary disease |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| ES2699257T3 (es) | 2013-02-28 | 2019-02-08 | Dermira Inc | Sales de glicopirrolato |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| US20140275517A1 (en) * | 2013-03-15 | 2014-09-18 | Pearl Therapeutics, Inc. | Methods and systems for conditioning of particulate crystalline materials |
| GB201305825D0 (en) * | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| SG11201700536XA (en) | 2014-09-09 | 2017-02-27 | Vectura Ltd | Formulation comprising glycopyrrolate, method and apparatus |
| CA2963146A1 (en) * | 2014-10-16 | 2016-04-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder formulation |
| US9925168B2 (en) * | 2016-01-22 | 2018-03-27 | Chiesi Farmaceutici S.P.A. | Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation |
| CA3016368A1 (en) | 2016-03-08 | 2017-09-14 | Mereo Biopharma 1 Limited | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions |
| KR102762199B1 (ko) | 2016-03-08 | 2025-02-07 | 메레오 바이오파마 1 리미티드 | 만성 폐쇄성 폐 질환의 급성 악화 치료를 위한 투약법 |
| US10888500B2 (en) | 2016-07-29 | 2021-01-12 | Inke, S.A. | Particle size stabilization process |
| CN114515284A (zh) | 2016-09-19 | 2022-05-20 | 墨西哥氟石股份公司 | 药物组合物 |
| US11219602B2 (en) | 2017-03-15 | 2022-01-11 | Vectura Limited | Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate |
| WO2019060604A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE MEDICINE |
| WO2019060595A1 (en) | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| PL3585383T3 (pl) | 2017-12-11 | 2021-07-05 | Mereo Biopharma 1 Limited | Zastosowanie 3-[5-amino-4-(3-cyjanobenzoilo)pirazol-1-ilo]- n-cyklopropylo- 4-metylobenzamidu w zapobieganiu ostrym zaostrzeniom przewlekłej obturacyjnej choroby płuc |
| ES2884789T3 (es) | 2017-12-11 | 2021-12-13 | Mereo Biopharma 1 Ltd | Uso de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciclopropil-4-metilbenzamida en el tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| KR102696616B1 (ko) | 2018-12-21 | 2024-08-20 | 한미약품 주식회사 | 흡입 제형용 건조 분말 및 이의 제조방법 |
| US20250058063A1 (en) | 2021-12-21 | 2025-02-20 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| CN118414147A (zh) | 2021-12-21 | 2024-07-30 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) * | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3709039A (en) * | 1970-08-31 | 1973-01-09 | Gen Time Corp | Comfort humidity indicator |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9808470D0 (en) | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
| DK1283036T3 (da) | 1998-11-13 | 2008-03-25 | Jagotec Ag | Törpulver til inhalation |
| GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| PT1913939T (pt) | 2000-06-27 | 2017-07-19 | Vectura Ltd | Formulações para utilização em dispositivos inalatórios |
| AU2211502A (en) * | 2000-11-30 | 2002-06-11 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| PT2283817T (pt) | 2000-11-30 | 2016-08-22 | Vectura Ltd | Método de fabrico de partículas para utilização numa composição farmacêutica |
| ATE375142T1 (de) * | 2001-03-30 | 2007-10-15 | Jagotec Ag | Medizinische aerosolformulierungen |
| JP2005530765A (ja) * | 2002-05-07 | 2005-10-13 | ネクター セラピューティクス | 乾燥粉末吸入器のためのカプセル及びそれを製造及び使用する方法 |
| GB2405798A (en) * | 2003-09-15 | 2005-03-16 | Vectura Ltd | Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device. |
| GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| JP2008534480A (ja) * | 2005-03-24 | 2008-08-28 | ソーセイ アールアンドディ リミテッド | グリコピロニウム塩およびそれらの治療的使用 |
-
2004
- 2004-04-30 GB GBGB0409703.6A patent/GB0409703D0/en not_active Ceased
-
2005
- 2005-04-29 CN CNA200580013592XA patent/CN1964700A/zh active Pending
- 2005-04-29 PT PT111906376T patent/PT2422766E/pt unknown
- 2005-04-29 SG SG10201605001SA patent/SG10201605001SA/en unknown
- 2005-04-29 HU HUE11190637A patent/HUE025463T2/en unknown
- 2005-04-29 NZ NZ550479A patent/NZ550479A/en not_active IP Right Cessation
- 2005-04-29 PT PT05738040T patent/PT1755555E/pt unknown
- 2005-04-29 SG SG2012093886A patent/SG186673A1/en unknown
- 2005-04-29 JP JP2007510045A patent/JP5000483B2/ja not_active Expired - Lifetime
- 2005-04-29 PL PL05738040T patent/PL1755555T3/pl unknown
- 2005-04-29 KR KR1020067024763A patent/KR101287919B1/ko not_active Expired - Lifetime
- 2005-04-29 ES ES05738040T patent/ES2388289T3/es not_active Expired - Lifetime
- 2005-04-29 SI SI200531570T patent/SI1755555T1/sl unknown
- 2005-04-29 PL PL11190637T patent/PL2422766T3/pl unknown
- 2005-04-29 US US11/587,725 patent/US20080063719A1/en not_active Abandoned
- 2005-04-29 WO PCT/EP2005/051980 patent/WO2005105043A2/en not_active Ceased
- 2005-04-29 SG SG200903001-6A patent/SG152292A1/en unknown
- 2005-04-29 CN CN201710357916.6A patent/CN107252423A/zh active Pending
- 2005-04-29 SI SI200531999T patent/SI2422766T1/sl unknown
- 2005-04-29 EP EP11190637.6A patent/EP2422766B1/en not_active Revoked
- 2005-04-29 AU AU2005237266A patent/AU2005237266B2/en active Active
- 2005-04-29 MX MXPA06012493A patent/MXPA06012493A/es active IP Right Grant
- 2005-04-29 DK DK05738040.4T patent/DK1755555T3/da active
- 2005-04-29 ES ES11190637.6T patent/ES2546982T3/es not_active Expired - Lifetime
- 2005-04-29 CN CN2010105642463A patent/CN102008453A/zh active Pending
- 2005-04-29 EP EP05738040A patent/EP1755555B1/en not_active Revoked
- 2005-04-29 BR BRPI0510500A patent/BRPI0510500B8/pt not_active IP Right Cessation
- 2005-04-29 DK DK11190637.6T patent/DK2422766T3/da active
- 2005-04-29 EP EP11190638A patent/EP2422767A3/en not_active Withdrawn
- 2005-04-29 RU RU2006142322/15A patent/RU2396943C2/ru active Protection Beyond IP Right Term
- 2005-04-29 CA CA2563760A patent/CA2563760C/en not_active Expired - Lifetime
-
2006
- 2006-10-16 IL IL178651A patent/IL178651A/en active IP Right Review Request
- 2006-10-27 MX MX2012008068A patent/MX341426B/es unknown
- 2006-11-10 ZA ZA2006/09350A patent/ZA200609350B/en unknown
- 2006-11-29 NO NO20065502A patent/NO20065502L/no not_active Application Discontinuation
-
2011
- 2011-02-09 AU AU2011200543A patent/AU2011200543B2/en not_active Expired
- 2011-11-08 JP JP2011244443A patent/JP5124718B2/ja not_active Expired - Lifetime
-
2012
- 2012-08-13 CY CY20121100722T patent/CY1113069T1/el unknown
- 2012-12-10 IL IL223545A patent/IL223545A/en active IP Right Grant
-
2013
- 2013-03-13 HU HUS1300006C patent/HUS1300006I1/hu unknown
- 2013-03-27 LU LU92176C patent/LU92176I2/fr unknown
- 2013-03-29 CY CY2013012C patent/CY2013012I2/el unknown
-
2014
- 2014-03-07 LU LU92392C patent/LU92392I2/xx unknown
- 2014-03-19 CY CY2014015C patent/CY2014015I1/el unknown
-
2015
- 2015-08-27 CY CY20151100754T patent/CY1116655T1/el unknown
- 2015-12-18 LT LTPA2015053C patent/LTC2422766I2/lt unknown
- 2015-12-21 HU HUS1500073C patent/HUS1500073I1/hu unknown
- 2015-12-21 HU HUS1500072C patent/HUS1500072I1/hu unknown
- 2015-12-23 CY CY2015059C patent/CY2015059I1/el unknown
- 2015-12-23 CY CY2015060C patent/CY2015060I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006142322A (ru) | Фармацевтические композиции | |
| US20050118272A1 (en) | Micronized pharmaceutical or nutraceutical powder with immediate release | |
| JP2007504103A5 (enExample) | ||
| JP2012031209A5 (enExample) | ||
| JP2015533134A (ja) | 錠剤の機械的安定性に適切な少なくとも１種の水和物形成活性物質及び／又はアジュバントを含有する機械的に安定な錠剤、特にアルギニン含有錠剤の製造における選択的に水分調整された打錠材料の使用 | |
| NZ573555A (en) | Nanoparticulate posaconazole formulations | |
| US4620974A (en) | Pharmaceutical composition containing a liquid lubricant | |
| KR20140011300A (ko) | 데페라시록스를 포함하는 약학 조성물 | |
| HRP20030592A2 (en) | Compositions of estrogen-cyclodextrin complexes | |
| JP2007145856A (ja) | カルベジロール製剤 | |
| MX2009002445A (es) | Uso de polioles para obtener formas polimorfas estables de rifaximina. | |
| JP2014515359A (ja) | ベンズイミダゾール誘導体を含む固形医薬組成物 | |
| JP5367735B2 (ja) | 錠剤の製造方法 | |
| CN101631549A (zh) | 贴附于口腔粘膜的丁丙诺非制剂的制造方法 | |
| JP6630343B2 (ja) | 抗酸化剤を含有する固形製剤 | |
| WO2019180735A1 (en) | Stable pharmaceutical compositions comprising sacubitril-valsartan complex | |
| JP2013010751A (ja) | クロピドグレル含有錠剤及びその製造方法 | |
| CN1636553A (zh) | 防挥发型固体制剂及其制造方法 | |
| EP1404303A1 (en) | Stable pharmaceutical compositions containing pravastatin | |
| WO2011141483A2 (en) | Stable pharmaceutical formulations containing an antihistaminic | |
| EP2585051B1 (en) | Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts | |
| CN104473888B (zh) | 一种阿折地平的药物组合物 | |
| WO2020003196A1 (en) | Pharmaceutical composition of axitinib | |
| DE602006004365D1 (de) | Feste orale darreichungsform des tribulinhemmstoffs indibulin | |
| WO2018079570A1 (ja) | 安定な医薬組成物 |